We further noted specific reactivation of BRAFi sensitivity in BRAFi-R melanoma cells following treatment with the p38 inhibitor BIRB 796, suggesting a specific mechanism of action for corin-associated resensitization of BRAFi-R melanomas to BRAFi therapies in this setting. This evidence concerns the gene CORIN and melanoma.